Aquestive Therapeutics Inc.
| NASDAQ: AQST | Healthcare / Biotechnology / USA |
| 2.39 | +0.1400 | +6.22% | Vol 970.55K | 1Y Perf 140.69% |
| Dec 1st, 2023 16:00 DELAYED |
| BID | 2.35 | ASK | 2.45 | ||
| Open | 2.35 | Previous Close | 2.25 | ||
| Pre-Market | - | After-Market | 2.45 | ||
| - - | 0.06 2.46% |
| Target Price | 6.38 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 166.95 | Finscreener Ranking | ★★★+ 51.56 | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★ 38.90 | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★+ 41.60 | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 84.77 | Earnings Rating | Strong Buy | |
| Market Cap | 159.57M | Earnings Date | 6th Nov 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.33 | |
| Beta | 2.61 |
Today's Price Range 2.262.48 | 52W Range 0.72002.69 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 12.74% | ||
| 1 Month | 65.97% | ||
| 3 Months | 43.11% | ||
| 6 Months | 5.75% | ||
| 1 Year | 140.69% | ||
| 3 Years | -64.43% | ||
| 5 Years | -72.18% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 79.92 | |||
ROE last 12 Months | 84.44 | |||
ROA (5Y Avg) | -65.03 | |||
ROA last 12 Months | -121.23 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -107.70 | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | -107.70 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 1.30 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.50 | ||||
| 14.15 | ||||
| 1.36 | ||||
| 38.20 | ||||
| -2.20 | ||||
| -0.58 | ||||
| -0.44 | ||||
| -1.99 | ||||
| 84.73M | ||||
| Forward PE | -6.23 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.80 | ||||
| 1.00 | ||||
| - | ||||
| - | ||||
| -4.00 | ||||
| Leverage Ratio | -0.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 63.70 | ||||
| -117.90 | ||||
| -112.20 | ||||
| -122.70 | ||||
| -91.51 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 37.00M | ||||
| 0.68 | ||||
| -3.11 | ||||
| -6.32 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.11 | -0.03 | 72.73 |
| Q02 2023 | -0.11 | -0.10 | 9.09 |
| Q01 2023 | -0.10 | 0.11 | 210.00 |
| Q04 2022 | -0.21 | -0.23 | -9.52 |
| Q03 2022 | -0.30 | -0.23 | 23.33 |
| Q02 2022 | -0.41 | -0.36 | 12.20 |
| Q01 2022 | -0.45 | -0.32 | 28.89 |
| Q04 2021 | -0.37 | -0.38 | -2.70 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | -0.08 | 55.56 | Positive |
| 12/2023 FY | -0.07 | 72.00 | Positive |
| 3/2024 QR | -0.10 | 16.67 | Positive |
| 12/2024 FY | -0.34 | 39.29 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | -0.11 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 970.55K |
| Shares Outstanding | 66.77K |
| Shares Float | 61.17M |
| Trades Count | 3.19K |
| Dollar Volume | 2.31M |
| Avg. Volume | 362.34K |
| Avg. Weekly Volume | 525.24K |
| Avg. Monthly Volume | 314.19K |
| Avg. Quarterly Volume | 247.58K |
Aquestive Therapeutics Inc. (NASDAQ: AQST) stock closed at 2.39 per share at the end of the most recent trading day (a 6.22% change compared to the prior day closing price) with a volume of 970.55K shares and market capitalization of 159.57M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 232 people. Aquestive Therapeutics Inc. CEO is Keith J. Kendall.
The one-year performance of Aquestive Therapeutics Inc. stock is 140.69%, while year-to-date (YTD) performance is 164.94%. AQST stock has a five-year performance of -72.18%. Its 52-week range is between 0.72 and 2.69, which gives AQST stock a 52-week price range ratio of 84.77%
Aquestive Therapeutics Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 14.15, a price-to-sale (PS) ratio of 1.36, a price to cashflow ratio of 38.20, a PEG ratio of -, a ROA of -121.23%, a ROC of -107.70% and a ROE of 84.44%. The company’s profit margin is -91.51%, its EBITDA margin is -112.20%, and its revenue ttm is $37.00 Million , which makes it $0.68 revenue per share.
Of the last four earnings reports from Aquestive Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.11 for the next earnings report. Aquestive Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Aquestive Therapeutics Inc. is Strong Buy (1), with a target price of $6.38, which is +166.95% compared to the current price. The earnings rating for Aquestive Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aquestive Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aquestive Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 18.44, ATR14 : 0.15, CCI20 : 162.77, Chaikin Money Flow : 0.19, MACD : 0.18, Money Flow Index : 88.67, ROC : 42.26, RSI : 74.25, STOCH (14,3) : 90.32, STOCH RSI : 1.00, UO : 58.93, Williams %R : -9.68), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aquestive Therapeutics Inc. in the last 12-months were:
Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. The product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS). Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, and Zuplenz. The products pipeline includes Exservan Oral Film, Libervant Buccal Film, AQST-119, AQST-108, and AQST-305.
CEO: Keith J. Kendall
Telephone: +1 908 941-1900
Address: 30 Technology Drive, Warren 07059, NJ, US
Number of employees: 232
TipRanks News for AQST
Tue, 10 Oct 2023 11:01 GMT Analysts Top Healthcare Picks: Aquestive Therapeutics (AQST), Guardant Health (GH)
- TipRanks. All rights reserved.Wed, 20 Sep 2023 19:52 GMT Setback for Neffy unlikely to affect Aquestives Anaphylm, says Alliance Global
- TipRanks. All rights reserved.Tue, 08 Aug 2023 15:25 GMT Aquestive Therapeutics (AQST) Receives a Buy from JMP Securities
- TipRanks. All rights reserved.
